Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome.
Pioglitazone monotherapy and combinations were assessed in patients with type 2 diabetes and metabolic syndrome (Adult Treatment Panel III criteria) from four worldwide randomised, multicentre, double-blind studies. Patients were treated for 52 weeks with.....